Oncolytics Biotech (TSE:ONC) had its price target reduced by equities research analysts at Royal Bank of Canada from C$10.00 to C$9.00 in a research report issued on Tuesday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 264.37% from the stock’s current price.
Oncolytics Biotech stock opened at C$2.47 on Tuesday. The company has a debt-to-equity ratio of 13.67, a quick ratio of 3.14 and a current ratio of 3.39. Oncolytics Biotech has a 12 month low of C$2.26 and a 12 month high of C$10.65. The firm has a market cap of $48.42 million and a PE ratio of -2.40.
Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Friday, March 8th. The company reported C($0.28) EPS for the quarter. As a group, equities analysts expect that Oncolytics Biotech will post -0.729999992438247 earnings per share for the current fiscal year.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Article: Return on Equity (ROE)